Gastric Cancer
Conditions
Brief summary
To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy
Interventions
DRUGTAS 102
35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
DRUGAnlotinib
10mg，per oral，once daily，days 1-14 of each 21-day cycle
Sponsors
Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years, ≤75 years * Histologically confirmed gastric cancer with distant metastasis * ECOG 0-1 * Progression on ≥ 2 lines of prior standard chemotherapy * Patients can swallow pills normally * Expected overall survival ≥6 months * Blood routine: no blood transfusion or blood products usage within 14 days, G-CSF or other hematopoietic stimulator was not used. WBC counts \> 3000/µl，Absolute neutrophil count (ANC) ≥ 1500 cells/µl，Platelet count ≥ 100,000/µl，Hemoglobin ≥ 9.0 g/dL. * AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum bilirubin ≤ 1.5 x ULN，creatinine\<ULN * Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN * Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment; * Informed consent has been signed.
Exclusion criteria
* Active bleeding within 3 months; Occurrence of arterial/venous thrombosis within 6 months; Hereditary or acquired bleeding (e.g., clotting dysfunction) or thrombotic tendencies; Full dose oral or injectable anticoagulants or thrombolytic drugs for therapeutic purposes are currently being used or have been used recently (10 days prior to the commencement of study treatment); Surgery (except for biopsy) was performed within 4 weeks prior to the study or the surgical incision was not fully healed; Aspirin (\> 325 mg/ day) or dipyridamole, ticlopidine, clopidogrel, and silotazole are currently being used or have recently been used (10 days prior to the study). * Certain or suspected brain metastases. * Patients who have received prior therapy of any study drug; * Serious uncontrolled systemic diseases, such as severe active infections; * A person is known to be infected with the immunodeficiency virus (HIV) or known to be HIV-positive; * Patients have suffered from other malignancies in the past 5 years except cervical carcinoma in situ or basal cell carcinoma of the skin * Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA \>500 IU/mL) or active HCV carriers with HCV RNA can be detected. Remarks: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA \< 500 IU/mL) may be enrolled * Anti-infective therapy was not discontinued 14 days before the study; * A prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia, and symptomatic interstitial lung disease or the presence of active pneumonia on a chest CT scan within 4 weeks prior to the study. * Patients have a history of intestinal obstruction within six months. Patients with incomplete obstruction syndrome of ileus at the time of initial diagnosis may be enrolled in the study if they have received definitive (surgical) treatment to resolve the symptoms, as assessed by the investigator. * Patients have high blood pressure that cannot be well controlled by antihypertensive medication (systolic ≥140 mmHg or diastolic ≥90 mmHg) * Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein \>1.0g; * Known to be allergic to any study drug; * Patients have participated in other drug clinical studies within 4 weeks before enrollment; * Lactating women * According to the judgment of the researcher, the patient may have other factors that may affect the results of the study or cause the study to be terminated, such as alcohol abuse, drug abuse, other serious diseases (including mental diseases) requiring combined treatment. Patients have severe laboratory abnormalities, which will affect the safety of the patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 4 months | The time elapsed between treatment initiation and tumor progression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | 2 months | the proportion of patients in a trial whose tumor is destroyed or significantly reduced by a drug. ORR is generally defined as the sum of complete responses (CRs) - patients with no detectable evidence of a tumor over a specified time period - and partial responses (PRs) - patients with a decrease in tumor size over a specified time period. |
| Overall Survival | 9 months | Refers to the time of death from enrollment to any cause |
Countries
China
Contacts
Primary ContactWeijia Fang, MD.
Outcome results
None listed